Impact of pharmacokinetic contrast of HMG-CoA reductase inhibitors: brief comunication

Abstract

Statins are drugs with the same mechanism of action that are indicated in the treatment of hypercholesterolemia and in the prevention of cardiovascular diseases associated with atherosclerosis, through enzymatic inhibition of HMG-CoA. In order to elucidate the questions about such differences, the pharmacokinetic differences between the inhibitors of the enzyme HMG-CoA reductase (statins) were investigated, and whether these differences, presumably, justify the amount of drugs on the market for the treatment of hypercholesterolemia. This study is characterized as a documentary research, with a quantitative and analytical-discursive approach, carried out through Micromedex solutions®, an international scientific platform used by health professionals in the clinic for the safe management of patient therapy. Results: Rosuvastatin, atorvastin and pitavastatin are the drugs with more superior differences in relation to the others that have shorter activities. The cost-benefit, similarity and quantity of HMG CoA reductase inhibitors leads us to believe that perhaps the total quantity of drugs present on the market with very similar characteristics, presumably, for pharmacological purposes is unnecessary. It is unnecessary from the pharmacokinetic and pharmacological point of view the large amount of drugs marketed for the same purpose, given that not all have justifiable differences to be placed on the market.